Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 469-478

  Bullano, Michael F ^a   Wertz, Debra A ^a   Yang, Grace W ^a   Kamat, Siddhesh ^a   Borok, Gerald M ^b   Gandhi, Sanjay ^b   McDonough, Kenneth L ^b   Willey, Vincent J ^a  

^a HEALTHCORE INC   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cholesterol; Dyslipidemia; LDL; Lipid; Low density lipoprotein cholesterol; National Cholesterol Education Program; NCEP; Rosuvastatin; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; DRUG EVALUATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROGRAM EVALUATION; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 33645682109     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.469     Document Type: Article

References (29)

1. American Heart Association. Heart disease and stroke statistics update: 2005 update. Dallas, TX: American Heart Association, 2004.
2. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary on the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation 2004;110(2):227-39.
5. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-52.
6. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000;139:577-83.
7. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
8. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
10. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
11. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-22.
12. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 1998;339:1349-57.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: west of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7.
14. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000;108(6):496-9.
15. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
16. AstraZeneca Pharmaceuticals. Crestor (rosuvastatin) package insert. Wilmington, DE; 2003.
17. Pfizer Inc. Lipitor (atorvastatin) package insert. New York, NY; revised 2004.
18. Bristol-Myers Squibb Co. Pravachol (pravastatin) package insert. Princeton, NJ; revised 2004.
19. Merck & Co., Inc. Mevacor (lovastatin) package insert. Whitehouse Station, NJ; 2004.
20. Merck & Co., Inc. Zocor (simvastatin) package insert. Whitehouse Station, NJ; 2004.
21. Novartis Pharmaceuticals. Lescol (fluvastatin) package insert. East Hanover, NJ; 2003.
22. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92(2):152-60.
23. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
24. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomized, double-blind study. J Cardiol Risk 2001;8:383-90.
25. McKenney JM, Jones P, Adamczyk M, Cain V, Bryzinski B, Blasetto J. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19(8):689-98.
26. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher D. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9.
27. Cannon CP, McCabe CH, Beider R, Breen J, Braunwald E. Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-1.
28. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
29. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89(3):268-75.